{
    "id": 20492,
    "fullName": "ERBB2 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) dec exp indicates decreased expression of the Erbb3 (Her3) protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "dec exp",
    "createDate": "03/31/2016",
    "updateDate": "10/10/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18464,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MP0274 induced apoptosis in breast cancer cells with low level Erbb2 (Her2) expression in culture and inhibited tumor growth in patient-derived xenograft (PDX) models (Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-30).",
            "molecularProfile": {
                "id": 20976,
                "profileName": "ERBB2 dec exp"
            },
            "therapy": {
                "id": 8663,
                "therapyName": "MP0274",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15958,
                    "pubMedId": null,
                    "title": "A bivalent Her2 targeting DARPin with high efficacy against Her2-low and Her2-positive tumors",
                    "url": "https://cancerres.aacrjournals.org/content/73/24_Supplement/P4-12-30"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5547,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines demonstrating lower basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) were resistant to Pan-HER in culture (PMID: 26420857).",
            "molecularProfile": {
                "id": 20977,
                "profileName": "EGFR dec exp ERBB2 dec exp ERBB3 dec exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5546,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung carcinoma cell lines demonstrating lower basal protein level of Egfr, Erbb2 (Her2) and Erbb3 (Her3) were resistant to Pan-HER in culture (PMID: 26420857).",
            "molecularProfile": {
                "id": 20977,
                "profileName": "EGFR dec exp ERBB2 dec exp ERBB3 dec exp"
            },
            "therapy": {
                "id": 3885,
                "therapyName": "Pan-HER",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5091,
                    "pubMedId": 26420857,
                    "title": "Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26420857"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 964,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",
            "molecularProfile": {
                "id": 23650,
                "profileName": "EGFR over exp ERBB2 dec exp"
            },
            "therapy": {
                "id": 910,
                "therapyName": "Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 6263,
                "name": "inflammatory breast carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 625,
                    "pubMedId": 24886365,
                    "title": "AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24886365"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 965,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",
            "molecularProfile": {
                "id": 23650,
                "profileName": "EGFR over exp ERBB2 dec exp"
            },
            "therapy": {
                "id": 1416,
                "therapyName": "Paclitaxel + Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 6263,
                "name": "inflammatory breast carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 625,
                    "pubMedId": 24886365,
                    "title": "AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24886365"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20976,
            "profileName": "ERBB2 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20977,
            "profileName": "EGFR dec exp ERBB2 dec exp ERBB3 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23650,
            "profileName": "EGFR over exp ERBB2 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}